AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company’s lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for AzurRx BioPharma, Inc. (AZRX)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
5 days ago | GlobeNewsWire
6 days ago | Pulse2
2 weeks ago | GlobeNewsWire
2 weeks ago | Pulse2
3 weeks ago | GlobeNewsWire
3 weeks ago | GlobeNewsWire
2 months ago | GlobeNewsWire
2 months ago | GlobeNewsWire
3 months ago | Benzinga